Non-Prescription Mast Cell Stabilizers: A Clinical Prescribing Protocol for Psychiatric Providers

Scope and Purpose

This protocol is intended for psychiatric providers working within the Holistic ImmunoPsychiatric (HIP) Framework who encounter patients with suspected or confirmed mast cell activation syndrome (MCAS) using or inquiring about non-prescription mast cell–stabilizing supplements. It provides an evidence-based framework for evaluating these products, understanding their mechanisms, assessing drug interactions with psychiatric medications, and counseling patients.

Critical Disclaimer: No non-prescription mast cell–stabilizing supplement has been evaluated in randomized controlled trials specifically for MCAS. The AAAAI Mast Cell Disorders Committee Work Group Report does not include any flavonoid or supplement among its recommended pharmacologic interventions for MCAS.[1] All recommendations below are based on preclinical evidence, pharmacokinetic studies, and clinical reasoning. These supplements should be considered adjunctive and should never replace established pharmacotherapy.

Section 1: Flavonoid Mast Cell Stabilizers

1A. Quercetin

Mechanism of Action

Quercetin inhibits mast cell activation through multiple pathways:

- Inhibits IgE-mediated degranulation and release of histamine, PGD₂, and leukotrienes from human mast cells[2]

- Blocks cytokine release (IL-6, IL-8, TNF-α) more effectively than cromolyn at equimolar concentrations[2]

- Suppresses the IL-33/ST2/NF-κB signaling cascade involved in mast cell activation[3]

- Inhibits MRGPRX2-mediated pseudo-allergic reactions via PLCγ-IP3R calcium signaling[4]

- Reduces cytosolic calcium increases and NF-κB activation[2]

- Acts prophylactically — effective when given before trigger exposure, unlike cromolyn which must be co-administered with the trigger[2]

Formulations and Bioavailability

Standard quercetin aglycone/dihydrate has approximately 6.7% oral bioavailability. Formulation choice dramatically affects absorption:

Formulation	Bioavailability Enhancement	Typical Dose	Notes	References
Quercetin dihydrate (standard)	Baseline (poor)	500–1000 mg BID	Least expensive; most widely available	[1]
Quercetin phytosome (Quercefit™)	~20-fold increase	250–500 mg daily	Phospholipid-complexed with lecithin; best-studied enhanced formulation	[1]
Quercetin + dietary fat/fiber	~2-fold increase	Food-based	Clinically relevant for dietary counseling	[1]
Cyclodextrin inclusion complex	~10.8-fold increase	Variable	Limited commercial availability	[1]

Clinical Evidence

- Two pilot, open-label clinical trials demonstrated that quercetin significantly decreased contact dermatitis and photosensitivity — skin conditions that do not respond to conventional treatment[2]

- No randomized controlled trials exist for quercetin in MCAS specifically

- In vivo animal studies confirm suppression of passive systemic anaphylaxis and passive cutaneous anaphylaxis[4]

Time-Dependent Sensitization Concern

A 2024 study found that while short-term quercetin exposure inhibits mast cell degranulation, prolonged exposure may transiently enhance non-IgE-mediated mast cell responsiveness through upregulated PKC activity.[6] This suggests:

- Periodic breaks from supplementation may be advisable

- Continuous high-dose use warrants monitoring

- Patients who initially improve but then worsen may be experiencing this phenomenon

Drug Interactions Relevant to Psychiatric Practice

Interaction	Mechanism	Clinical Significance	References
Fexofenadine (Allegra)	P-glycoprotein inhibition	AUC increased 55%, Cmax increased 68% at quercetin 500 mg TID × 7 days. Most MCAS patients take fexofenadine — this is the most clinically relevant interaction	[1]
Benzodiazepines (midazolam, alprazolam)	CYP3A4 inhibition/induction (bidirectional)	Unpredictable effects on CYP3A4-metabolized benzodiazepines; may increase or decrease levels depending on dose and duration	[2]
Warfarin	Albumin displacement + CYP2C9 inhibition	Strongly displaces warfarin from serum albumin; may increase free warfarin and bleeding risk	[3]
Cyclosporine	CYP3A4 induction by metabolites	May reduce cyclosporine levels	[2]
SSRIs/SNRIs	Theoretical CYP interaction	Limited direct data; monitor for altered efficacy	—

Safety Considerations

- Doses >1 g/day: reports of kidney damage; avoid in pre-existing renal disease[10]

- Estrogen-dependent conditions: animal data suggest potential tumor promotion; use caution in patients with ER+ cancer history[10]

- Long-term safety data (>12 weeks at ≥1000 mg) are inadequate[10]

- Pregnancy/breastfeeding: insufficient safety data; avoid[11]

Prescribing Approach

1. Start low: 250 mg quercetin phytosome daily (or 500 mg standard quercetin daily)

2. Titrate slowly over 2–4 weeks; MCAS patients may react to excipients

3. Take with a fat-containing meal to enhance absorption

4. Consider periodic breaks (e.g., 5 days on / 2 days off, or 3 weeks on / 1 week off) given time-dependent sensitization data[6]

5. Review all concurrent medications for P-gp and CYP3A4 interactions

6. If patient is on fexofenadine, counsel about the 55–68% increase in fexofenadine exposure[7]

1B. Luteolin

Mechanism of Action

Luteolin is significantly more potent than cromolyn at inhibiting mediator release from cultured human mast cells:[12]

- Inhibits histamine, tryptase, MMP-9, and VEGF release from human LADR mast cells[12]

- Inhibits IL-1β, IL-6, IL-8, and TNF release — effects that cromolyn does not achieve at all[12]

- Suppresses IL-31 production in IL-33-stimulated mast cells through MAPK and NF-κB pathways[13]

- Promotes regulatory T cell (Treg) differentiation while suppressing Th17 and Th2 responses[14]

- Skews macrophage polarization toward anti-inflammatory M2 phenotype[14]

- Inhibits NLRP3 inflammasome activation[14]

Unique Neuropsychiatric Properties

Luteolin has direct CNS activity relevant to psychiatric practice:

- Selective inhibitor of human MAO-A (IC₅₀ = 8.57 µM) with minimal MAO-B inhibition (IC₅₀ >100 µM)[15]

- Antagonist at dopamine D₄ receptor and vasopressin V₁ᴀ receptor[15]

- Suppresses microglial activation and neuroinflammation via NF-κB and MAPK pathways[16][17]

- A liposomal luteolin formulation in olive fruit extract improved attention in children with ASD and brain fog in mastocytosis patients[18]

Bioavailability

Like quercetin, luteolin has poor oral bioavailability due to extensive first-pass metabolism by phase II enzymes and active P-glycoprotein efflux.[19][20] Key formulation data:

Formulation	Bioavailability Enhancement	Notes	References
Free luteolin (standard)	Baseline (poor)	Rapidly conjugated to glucuronides and sulfates	[1]
Phospholipid complex (LPC)	Improved (magnitude not precisely quantified in humans)	Enhanced solubility; better efficacy in animal inflammation models	[1]
Liposomal luteolin in olive fruit extract	Improved (clinical observations)	Used in the Theoharides ASD/mastocytosis studies; basis for NeuroProtek-type formulations	[2]
Microemulsion system	~2.2-fold increase (rat AUC)	Better water dispersibility	[3]
Self-microemulsifying system (TPGS-based)	~29-fold increase (rat AUC)	Inhibits P-gp efflux; not yet commercially available	[4]
Nanosuspension	Significant increase (magnitude varies)	Scalable approach; preclinical stage	[5]
β-Cyclodextrin/CaCO₃ microcomposite	2.34–3.36-fold increase	Novel approach; preclinical	[6]

Drug Interactions Relevant to Psychiatric Practice

Interaction	Mechanism	Clinical Significance	References
Midazolam and other CYP3A4 substrates	CYP3A4 inhibition (Ki 30–50 µM)	Inhibits formation of both 1'-OH-midazolam and 4-OH-midazolam; may increase levels of CYP3A4-metabolized benzodiazepines, buspirone, certain atypical antipsychotics	[1]
CYP1A1 substrates	AhR pathway modulation	Inhibits CYP1A1 expression; may affect metabolism of some drugs	[2]
OATP1B1/OATP2B1 substrates	Transporter inhibition by luteolin conjugates	Luteolin metabolites (sulfate/glucuronide conjugates) are potent inhibitors of hepatic uptake transporters; may affect statins and other OATP substrates	[3]
MAO-A substrates	Direct MAO-A inhibition	Selective MAO-A inhibition at IC₅₀ ~8.6 µM; theoretical risk of serotonin syndrome with SSRIs/SNRIs at high doses, though dietary-level exposure is unlikely to reach this threshold	[4]

The MAO-A Interaction Deserves Special Attention in Psychiatric Practice

Luteolin's selective MAO-A inhibition is a double-edged sword. It may contribute to its antidepressant and anxiolytic properties, but it also creates a theoretical interaction risk with serotonergic medications. At typical supplement doses with poor bioavailability, clinically significant MAO-A inhibition is unlikely. However, with enhanced-bioavailability formulations, this interaction becomes more plausible and should be monitored.

Prescribing Approach

1. Start with 100 mg luteolin daily in a lipid-based or liposomal formulation

2. Titrate to 200–400 mg daily over 2–4 weeks as tolerated

3. Take with food containing fat to enhance absorption

4. Review concurrent serotonergic medications given MAO-A inhibitory activity[15]

5. Review concurrent benzodiazepine use given CYP3A4 inhibition[24]

6. Monitor for paradoxical worsening, which may indicate excipient sensitivity in MCAS patients

1C. Palmitoylethanolamide (PEA)

Mechanism of Action

PEA is an endogenous fatty acid amide (N-acylethanolamine) that the body produces naturally to downregulate mast cell activation:[27][28]

- Directly downregulates mast cell degranulation via the "ALIA" (Autacoid Local Injury Antagonism) mechanism[29]

- Activates PPARα and GPR55 nuclear receptors, reducing pro-inflammatory cellular behavior[29]

- Enhances endocannabinoid signaling ("entourage effect") by stimulating 2-AG biosynthesis via DAGL enzymes, which then activates CB2 receptors to suppress mast cell activation[30]

- Inhibits histamine, PGD₂, and TNF-α release from mast cells in a concentration-dependent manner[31]

- PEA and luteolin act synergistically — their combination prevents mast cell degranulation and reduces mast cell-mediated neurotoxicity more effectively than either compound alone[32]

Bioavailability

Native PEA has limited bioavailability due to its lipophilic nature. Micronized (m-PEA) and ultramicronized (um-PEA) formulations have been developed to overcome this limitation and have been used in both preclinical and clinical studies.[29]

Formulation	Notes	References
Standard PEA	Limited bioavailability; lipophilic	[1]
Micronized PEA (m-PEA)	Improved absorption; used in clinical studies	[1]
Ultramicronized PEA (um-PEA)	Best-studied formulation; particle size reduction enhances absorption	[1]
Co-micronized PEA + polydatin	Combination product studied for chronic pain	[1]
PEA + luteolin combinations	Synergistic mast cell stabilization and neuroprotection	[2]

Clinical Evidence

PEA has the most extensive clinical trial data of any compound in this protocol, though primarily in pain and neuroinflammation rather than MCAS specifically:

- Multiple clinical studies in chronic pelvic pain, neuropathic pain, and neuroinflammatory conditions[29]

- Classified as a "dietary food for special medical purposes" in some jurisdictions[30]

- Endogenous PEA levels are elevated in mastocytosis patients, suggesting a compensatory protective mechanism[33]

Drug Interactions

PEA has a favorable interaction profile compared to the flavonoids:

- No significant CYP450 interactions reported

- Enhances endocannabinoid signaling, which could theoretically interact with cannabinoid-based medications

- Generally well-tolerated with minimal reported adverse effects

Prescribing Approach

1. Start with 300–400 mg ultramicronized PEA daily

2. Titrate to 600–1200 mg daily in divided doses over 2–4 weeks

3. Consider combination with luteolin for synergistic mast cell stabilization[32]

4. PEA has the most favorable safety and interaction profile of the three compounds discussed

5. May be particularly useful for patients with comorbid neuropathic pain or neuroinflammation

Section 2: Postbiotics — Short-Chain Fatty Acids and Dietary Fiber

Mechanism

Short-chain fatty acids (SCFAs), particularly butyrate and valerate, produced by gut bacteria from dietary fiber fermentation, represent a physiologically distinct approach to mast cell stabilization:

- Oral administration of butyrate or valerate ameliorates passive systemic anaphylaxis and passive cutaneous anaphylaxis in mice[34]

- Butyrate inhibits both IgE-mediated and non-IgE-mediated human mast cell degranulation[35]

- Mechanism involves epigenetic regulation: butyrate acts as an HDAC inhibitor, selectively targeting super-enhancers that control core mast cell identity genes (BTK, SYK, LAT)[36][35]

- Butyrate also signals through GPR109A receptors and enhances PGE₂ release, which suppresses mast cell activation via EP3 receptors[34]

- Dietary fiber intake directly determines SCFA production and influences mucosal immunity, regulatory T cell numbers, and gut epithelial integrity[37]

Clinical Relevance

This pathway provides the mechanistic rationale for emphasizing high-fiber diets over fermented food consumption in MCAS patients. Dietary fiber achieves mast cell stabilization through SCFA production without the histamine burden of fermented foods.

Postbiotic Supplements

Tributyrin (a butyrate prodrug) and sodium butyrate supplements are commercially available. While no clinical trials exist specifically for MCAS, the preclinical evidence for mast cell stabilization is robust.[34][36][35] Typical supplement doses range from 300–600 mg tributyrin, 1–2 times daily.

Section 3: Probiotic and Postbiotic Strain Guide

How to Evaluate a Patient's Probiotic Supplement

When a patient brings in a probiotic bottle, evaluate it using this framework:

Step 1: Check for histamine-producing strains (RED FLAGS)

The following species/strains have documented histamine-producing capacity and should be flagged:

Species	Histamine Production	Clinical Concern	References
Lactobacillus reuteri (most strains)	High (8,510+ ng/mL)	Paradoxical: produces histamine but suppresses TNF via H2 receptor. Dual role makes it unpredictable in MCAS	[1], [2]
Morganella morganii	Very high (up to 82,400 ng/mL)	Not a probiotic species but may contaminate poorly manufactured products	[1]
Lactobacillus vaginalis	Moderate	Found at higher frequency in asthmatic patients	[3]
Lactobacillus bulgaricus	Variable	Common in yogurt cultures; may produce histamine	—
Streptococcus thermophilus	Variable	Common in yogurt cultures; histamine production is strain-dependent	—
Enterococcus faecalis/faecium	Variable	Some strains possess histidine decarboxylase genes	[4]

Important nuance regarding L. reuteri: This species produces substantial histamine via its histidine decarboxylase gene cluster. However, the histamine it produces acts primarily through the H2 receptor to suppress TNF-α production via PKA/ERK signaling.[39] This means L. reuteri can paradoxically have anti-inflammatory effects despite producing histamine. For MCAS patients, this dual role makes it unpredictable — some may benefit, others may worsen. It should be approached with caution and individualized monitoring.

Step 2: Identify mast cell–stabilizing strains (GREEN FLAGS)

Species/Strain	Mechanism	Evidence Level	References
Lactobacillus rhamnosus GG (LGG)	Downregulates FcεRI (high-affinity IgE receptor) and H4 receptor gene expression; upregulates anti-inflammatory IL-10	In vitro (human mast cells)	[1]
Lactobacillus rhamnosus JB-1	Directly stabilizes mast cells by inhibiting KCa3.1 potassium channel critical to degranulation; reduces passive cutaneous anaphylaxis in vivo	In vivo (rat)	[2]
Lactobacillus rhamnosus Lc705	Downregulates FcεRI and H4 receptor; suppresses pro-inflammatory cytokines	In vitro (human mast cells)	[1]
Lacticaseibacillus casei	Suppresses mast cell granule formation via epigenetic regulation (C/EBPα-dependent)	In vitro	[3]
Bifidobacterium animalis ssp. lactis Bb12	Modulates mast cell immune regulation in combination with L. rhamnosus strains	In vitro (human mast cells)	[1]
Bifidobacterium longum ssp. infantis	Decreases mast cell degranulation in food allergy models; suppresses histamine signaling (H1R and HDC gene expression)	In vivo (rat/mouse)	[4], [5]
Lactobacillus salivarius	Blocks Th1/Th2 responses; reduces mast cell degranulation	In vivo (mouse)	[4]

Step 3: Identify histamine-degrading strains (BONUS)

Species/Strain	Mechanism	References
Lactobacillus paracasei (certain strains)	Actively degrades histamine enzymatically	[1]
Lactiplantibacillus plantarum (certain strains, e.g., D-103, SQ1)	Possesses histamine oxidase activity; degrades histamine via multicopper oxidase (cueO) pathway; achieved 42% histamine degradation in fermented food models	[2], [3]

Step 4: Assess the overall microbiome context

Patients with histamine intolerance show characteristic dysbiosis:[50]

- Increased Proteobacteria

- Reduced alpha-diversity

- Significantly reduced Bifidobacteriaceae (lowest levels compared to all other groups)

- Reduced Butyricimonas (a butyrate producer)

- Elevated stool zonulin (indicating intestinal barrier dysfunction)

This pattern suggests that Bifidobacterium-dominant formulations may be particularly beneficial for this population, while products heavy in Lactobacillus species require strain-level scrutiny.

Quick-Reference: Evaluating a Patient's Probiotic Bottle

When a patient presents a probiotic supplement, use this checklist:

1. Read the strain designations, not just the species names

- Effects are strain-specific. "Lactobacillus rhamnosus GG" is mast cell–stabilizing; a generic "Lactobacillus rhamnosus" without strain designation is unknown[43][42]

- Products listing only genus and species without strain identifiers cannot be evaluated for mast cell effects

2. Flag any histamine-producing species

- L. reuteri — counsel about dual role; monitor closely

- L. bulgaricus, S. thermophilus — common in yogurt-based probiotics; variable histamine production

3. Look for mast cell–stabilizing strains

- L. rhamnosus GG, JB-1, or Lc705 — favorable evidence

- B. infantis, B. longum, B. animalis ssp. lactis Bb12 — favorable evidence

- L. paracasei, L. plantarum — potential histamine-degrading benefit

4. Check for unnecessary additives

- Prebiotics (FOS, inulin) may cause GI symptoms in sensitive patients

- Fillers, colorants, and flavoring agents may trigger MCAS reactions

- Dairy-derived ingredients may be problematic for histamine-intolerant patients

5. Assess label accuracy

- A 2025 metagenomic analysis found that only 37% of predominant microorganisms identified by metagenomics were accurately listed on product labels[51]

- Third-party tested products (USP, NSF, ConsumerLab) are preferred

6. Consider postbiotic alternatives

- For patients who cannot tolerate any live probiotic, tributyrin/sodium butyrate supplements provide the mast cell–stabilizing benefits of SCFAs without introducing live organisms[34][36][35]

- High-fiber dietary counseling remains the most physiologic approach to increasing endogenous SCFA production[37]

Section 4: Combination Strategies and Practical Protocols

Suggested Tiered Approach

Tier 1 — Dietary Foundation (All Patients)

- Anti-inflammatory dietary pattern (Mediterranean-style) adapted to individual tolerances

- Emphasis on high-fiber foods to promote endogenous SCFA/butyrate production[37]

- Quercetin-rich foods (onions, apples, berries, broccoli, kale) consumed with dietary fat[5]

- Luteolin-rich foods (celery, parsley, thyme, chamomile tea, peppers)

- Avoid fermented foods if histamine-intolerant; emphasize fiber over fermentation

Tier 2 — Single-Agent Supplementation (After Provider Discussion)

- PEA (ultramicronized): 300–600 mg daily, titrate to 600–1200 mg daily

- Favorable safety profile; fewest drug interactions; endogenous compound

- OR Quercetin phytosome: 250 mg daily, titrate to 250–500 mg daily

- Review fexofenadine and CYP3A4 interactions before starting

- OR Luteolin (liposomal/lipid-based): 100 mg daily, titrate to 200–400 mg daily

- Review MAO-A and CYP3A4 interactions before starting

Tier 3 — Combination Supplementation (Refractory Patients)

- PEA + luteolin: Synergistic mast cell stabilization demonstrated in preclinical models[32]

- Quercetin + targeted probiotic (L. rhamnosus GG or B. infantis-based formulation)

- Consider adding tributyrin 300–600 mg daily if fiber intake is inadequate

Monitoring Parameters

- Symptom diary (use the R&R Food and Symptom Diary worksheet)

- Baseline and follow-up tryptase levels if available

- Monitor for paradoxical worsening (may indicate excipient sensitivity or time-dependent sensitization)

- Review medication list at each visit for new interaction risks

- Reassess at 4–8 weeks; if no benefit, discontinue rather than escalating indefinitely

Section 5: Summary Table — Non-Rx Mast Cell Stabilizers at a Glance

Compound	Potency vs. Cromolyn	Best Formulation	Starting Dose	Key Drug Interactions	Evidence Level
Quercetin	More effective for cytokine inhibition	Phytosome (20× bioavailability)	250 mg phytosome daily	Fexofenadine (↑55% AUC), CYP3A4 substrates, warfarin	In vitro + 2 pilot clinical trials	[1], [2], [3]
Luteolin	More potent across all mediators tested	Liposomal/lipid-based	100 mg daily	MAO-A inhibition, CYP3A4 substrates (midazolam), OATP transporters	In vitro + observational clinical reports	[4], [5], [6]
PEA	Different mechanism (ALIA/endocannabinoid)	Ultramicronized (um-PEA)	300–600 mg daily	Minimal; favorable profile	In vitro + multiple clinical trials (pain/neuroinflammation)	[7], [8], [9]
Butyrate	Different mechanism (epigenetic/HDAC)	Tributyrin or sodium butyrate	300–600 mg daily	Minimal	In vitro + in vivo animal	[10], [11], [12]

---

Limitations and Caveats

1. No RCTs exist for any of these compounds specifically in MCAS. All mast cell–stabilizing evidence is from in vitro studies, animal models, or clinical trials in other conditions.

2. Concentrations used in laboratory experiments often exceed achievable tissue levels from oral supplementation, even with enhanced-bioavailability formulations.

3. MCAS patients are uniquely susceptible to supplement reactions — excipients, fillers, colorants, and even the active compounds themselves may trigger mast cell activation. Start low, go slow.

4. Supplement quality is unregulated. Only 37% of probiotic products accurately list their contents. Recommend third-party tested products.[51]

5. These supplements do not replace established MCAS pharmacotherapy (H1/H2 antihistamines, cromolyn, leukotriene receptor antagonists, omalizumab).[1]

6. The probiotic strain data is predominantly preclinical. No clinical trials have evaluated specific probiotic strains for MCAS outcomes.

References

1. AAAAI Mast Cell Disorders Committee Work Group Report: Mast Cell Activation Syndrome (MCAS) Diagnosis and Management. Weiler CR, Austen KF, Akin C, et al. The Journal of Allergy and Clinical Immunology. 2019;144(4):883-896. doi:10.1016/j.jaci.2019.08.023.

2. Quercetin Is More Effective Than Cromolyn in Blocking Human Mast Cell Cytokine Release and Inhibits Contact Dermatitis and Photosensitivity in Humans. Weng Z, Zhang B, Asadi S, et al. PloS One. 2012;7(3):e33805. doi:10.1371/journal.pone.0033805.

3. Quercetin Modulates Mast Cell Activation and the IL-33/ST2/NF-κB Axis in Allergic Rhinitis. Xiao Y, Xu M, Zhong L, et al. Scientific Reports. 2026;:10.1038/s41598-026-57981-6. doi:10.1038/s41598-026-57981-6.

4. Quercetin Inhibits Mrgprx2-Induced Pseudo-Allergic Reaction via PLCγ-IP3R Related Ca Fluctuations. Ding Y, Che D, Li C, et al. International Immunopharmacology. 2019;66:185-197. doi:10.1016/j.intimp.2018.11.025.

5. Improving Quercetin Bioavailability: A Systematic Review and Meta-Analysis of Human Intervention Studies. Liu L, Barber E, Kellow NJ, Williamson G. Food Chemistry. 2025;477:143630. doi:10.1016/j.foodchem.2025.143630.

6. Time-Sensitive Effects of Quercetin on Rat Basophilic Leukemia (RBL-2H3) Cell Responsiveness and Intracellular Signaling. Matsuo M, Liu S, Yamada H, et al. PloS One. 2025;20(2):e0319103. doi:10.1371/journal.pone.0319103.

7. Short-Term Effect of Quercetin on the Pharmacokinetics of Fexofenadine, a Substrate of P-Glycoprotein, in Healthy Volunteers. Kim KA, Park PW, Park JY. European Journal of Clinical Pharmacology. 2009;65(6):609-14. doi:10.1007/s00228-009-0627-6.

8. Interactions between CYP3A4 and Dietary Polyphenols. Basheer L, Kerem Z. Oxidative Medicine and Cellular Longevity. 2015;2015:854015. doi:10.1155/2015/854015.

9. Interaction of Quercetin and Its Metabolites With Warfarin: Displacement of Warfarin From Serum Albumin and Inhibition of CYP2C9 Enzyme. Poór M, Boda G, Needs PW, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2017;88:574-581. doi:10.1016/j.biopha.2017.01.092.

10. Safety Aspects of the Use of Quercetin as a Dietary Supplement. Andres S, Pevny S, Ziegenhagen R, et al. Molecular Nutrition & Food Research. 2018;62(1). doi:10.1002/mnfr.201700447.

11. Nature nominee quercetin's anti‐influenza combat strategy—Demonstrations and remonstrations. Gansukh E, Muthu M, Paul D, et al. Reviews in Medical Virology. 2017;27(3):e1930. doi:10.1002/rmv.1930.

12. Luteolin Is More Potent Than Cromolyn in Their Ability to Inhibit Mediator Release From Cultured Human Mast Cells. Tsilioni I, Theoharides T. International Archives of Allergy and Immunology. 2024;185(8):803-809. doi:10.1159/000537752.

13. The Role of Mast Cells in Skin Aging: Mechanisms and Therapeutic Advances. Zhou L, Cao Z, Shen S, et al. Experimental Dermatology. 2025;34(11):e70173. doi:10.1111/exd.70173.

14. Luteolin as a Multifaceted Immunomodulator: Insights Into Its Effects on Diverse Immune Cell Populations and Therapeutic Implications. Wang X, Zhao J, Li Y, Gao S, Su L. Frontiers in Immunology. 2025;16:1621367. doi:10.3389/fimmu.2025.1621367.

15. Luteolin, a Potent Human Monoamine Oxidase-a Inhibitor and Dopamine D and Vasopressin v Receptor Antagonist. Park SE, Paudel P, Wagle A, et al. Journal of Agricultural and Food Chemistry. 2020;68(39):10719-10729. doi:10.1021/acs.jafc.0c04502.

16. Exploring the Mechanism of Luteolin by Regulating Microglia Polarization Based on Network Pharmacology and in Vitro Experiments. Wang T, Yin Y, Jiang X, et al. Scientific Reports. 2023;13(1):13767. doi:10.1038/s41598-023-41101-9.

17. Luteolin and Neuroinflammation: A Multi-Target Therapeutic Strategy for Central Nervous System Disorders. Huang J, Yu M, Zou Y, et al. Frontiers in Pharmacology. 2026;17:1844585. doi:10.3389/fphar.2026.1844585.

18. Brain "Fog," Inflammation and Obesity: Key Aspects of Neuropsychiatric Disorders Improved by Luteolin. Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Frontiers in Neuroscience. 2015;9:225. doi:10.3389/fnins.2015.00225.

19. Paving Luteolin Therapeutic Potentialities and Agro‐Food‐Pharma Applications: Emphasis on In Vivo Pharmacological Effects and Bioavailability Traits. Taheri Y, Sharifi-Rad J, Antika G, et al. Oxidative Medicine and Cellular Longevity. 2021;2021:1987588. doi:10.1155/2021/1987588.

20. Boosting Luteolin Bioavailability via P-Glycoprotein Efflux Inhibition: A Self-Microemulsifying Drug Delivery Systems. Zheng Y, Chen B, Huang X, et al. Journal of Advanced Research. 2026;:S2090-1232(26)00055-X. doi:10.1016/j.jare.2026.01.030.

21. Improving Water Dispersibility and Bioavailability of Luteolin Using Microemulsion System. Miyashita A, Ito J, Parida IS, et al. Scientific Reports. 2022;12(1):11949. doi:10.1038/s41598-022-16220-4.

22. Improvement of Aqueous Solubility and Oral Bioavailability of Luteolin: A Nanosuspension Approach. Sripadi HP, Andugulapati SB, U V R VS, Sistla R. Drug Development and Industrial Pharmacy. 2026;52(6):1132-1146. doi:10.1080/03639045.2026.2655893.

23. Calcium Carbonate Hybrid Microcomposite for Oral Delivery of Luteolin, a Poorly Water-Soluble Phytocompound. Hong JK, Kang Y, Seo SW, et al. Food Chemistry. 2025;:147602. doi:10.1016/j.foodchem.2025.147602.

24. Flavonoids Diosmetin and Luteolin Inhibit Midazolam Metabolism by Human Liver Microsomes and Recombinant CYP 3A4 and CYP3A5 Enzymes. Quintieri L, Palatini P, Nassi A, Ruzza P, Floreani M. Biochemical Pharmacology. 2008;75(6):1426-37. doi:10.1016/j.bcp.2007.11.012.

25. Luteolin Modulates Expression of Drug-Metabolizing Enzymes Through the AhR and Nrf2 Pathways in Hepatic Cells. Zhang T, Kimura Y, Jiang S, et al. Archives of Biochemistry and Biophysics. 2014;557:36-46. doi:10.1016/j.abb.2014.05.023.

26. Interaction of Luteolin, Naringenin, and Their Sulfate and Glucuronide Conjugates With Human Serum Albumin, Cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) Enzymes and Organic Anion Transporting Polypeptide (OATP1B1 and OATP2B1) Transporters. Kaci H, Bodnárová S, Fliszár-Nyúl E, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2023;157:114078. doi:10.1016/j.biopha.2022.114078.

27. New Insights in Mast Cell Modulation by Palmitoylethanolamide. De Filippis D, Negro L, Vaia M, Cinelli MP, Iuvone T. CNS & Neurological Disorders Drug Targets. 2013;12(1):78-83. doi:10.2174/1871527311312010013.

28. Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-Inflammatory and Neuroprotective Lipid Mediator. Skaper SD, Facci L, Giusti P. Molecular Neurobiology. 2013;48(2):340-52. doi:10.1007/s12035-013-8487-6.

29. Looking for Responders among Women with Chronic Pelvic Pain Treated with a Comicronized Formulation of Micronized Palmitoylethanolamide and Polydatin. Indraccolo U, Favilli A, Dell'Anna A, et al. BioMed Research International. 2022;2022:8620077. doi:10.1155/2022/8620077.

30. Palmitoylethanolamide Counteracts Substance P-Induced Mast Cell Activation in Vitro by Stimulating Diacylglycerol Lipase Activity. Petrosino S, Schiano Moriello A, Verde R, et al. Journal of Neuroinflammation. 2019;16(1):274. doi:10.1186/s12974-019-1671-5.

31. Effects of Palmitoylethanolamide on Immunologically Induced Histamine, PGD2 and TNFalpha Release From Canine Skin Mast Cells. Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. Veterinary Immunology and Immunopathology. 2010;133(1):9-15. doi:10.1016/j.vetimm.2009.06.011.

32. PEA and Luteolin Synergistically Reduce Mast Cell-Mediated Toxicity and Elicit Neuroprotection in Cell-Based Models of Brain Ischemia. Parrella E, Porrini V, Iorio R, et al. Brain Research. 2016;1648(Pt A):409-417. doi:10.1016/j.brainres.2016.07.014.

33. Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N ‐Acylethanolamines in Patients with Mastocytosis. Ferrara AL, Piscitelli F, Petraroli A, et al. Journal of Immunology Research. 2019;2019:5836476. doi:10.1155/2019/5836476.

34. Butyrate, Valerate, and Niacin Ameliorate Anaphylaxis by Suppressing IgE-Dependent Mast Cell Activation: Roles of GPR109A, PGE2, and Epigenetic Regulation. Nagata K, Ando D, Ashikari T, et al. Journal of Immunology (Baltimore, Md. : 1950). 2024;212(5):771-784. doi:10.4049/jimmunol.2300188.

35. Butyrate Inhibits Human Mast Cell Activation via Epigenetic Regulation of FcεRI-mediated Signaling. Folkerts J, Redegeld F, Folkerts G, et al. Allergy. 2020;75(8):1966-1978. doi:10.1111/all.14254.

36. Butyrate Selectively Targets Super-Enhancers and Transcriptional Networks Associated With Human Mast Cell Function. Folkerts J, de Bruijn MJW, van IJcken WFJ, Hendriks RW, Stadhouders R. European Journal of Immunology. 2025;55(6):e51680. doi:10.1002/eji.202451680.

37. Dietary Fiber and SCFAs in the Regulation of Mucosal Immunity. Tan JK, Macia L, Mackay CR. The Journal of Allergy and Clinical Immunology. 2023;151(2):361-370. doi:10.1016/j.jaci.2022.11.007.

38. Phylogenetically Diverse Bacterial Species Produce Histamine. Engevik KA, Hazzard A, Puckett B, et al. Systematic and Applied Microbiology. 2024;47(5):126539. doi:10.1016/j.syapm.2024.126539.

39. Histamine Derived From Probiotic Lactobacillus Reuteri Suppresses TNF via Modulation of PKA and ERK Signaling. Thomas CM, Hong T, van Pijkeren JP, et al. PloS One. 2012;7(2):e31951. doi:10.1371/journal.pone.0031951.

40. Role of Histamine in Modulating the Immune Response and Inflammation. Branco ACCC, Yoshikawa FSY, Pietrobon AJ, Sato MN. Mediators of Inflammation. 2018;2018:9524075. doi:10.1155/2018/9524075.

41. The Taxonomic Distribution of Histamine-Secreting Bacteria in the Human Gut Microbiome. Mou Z, Yang Y, Hall AB, Jiang X. BMC Genomics. 2021;22(1):695. doi:10.1186/s12864-021-08004-3.

42. Probiotic Lactobacillus Rhamnosus Downregulates FCER1 and HRH4 Expression in Human Mast Cells. Oksaharju A, Kankainen M, Kekkonen RA, et al. World Journal of Gastroenterology. 2011;17(6):750-9. doi:10.3748/wjg.v17.i6.750.

43. Systemic Effects of Ingested Lactobacillus Rhamnosus: Inhibition of Mast Cell Membrane Potassium (IKCa) Current and Degranulation. Forsythe P, Wang B, Khambati I, Kunze WA. PloS One. 2012;7(7):e41234. doi:10.1371/journal.pone.0041234.

44. CCAAT/enhancer-binding Protein Α-Dependent Regulation of Granule Formation in Mast Cells by Intestinal Bacteria. Iketani A, Takano M, Kasakura K, et al. European Journal of Immunology. 2024;54(10):e2451094. doi:10.1002/eji.202451094.

45. Three Novel Candidate Probiotic Strains With Prophylactic Properties in a Murine Model of Cow's Milk Allergy. Neau E, Delannoy J, Marion C, et al. Applied and Environmental Microbiology. 2016;82(6):1722-1733. doi:10.1128/AEM.03440-15.

46. Suppression of Histamine Signaling by Probiotic Lac-B: A Possible Mechanism of Its Anti-Allergic Effect. Dev S, Mizuguchi H, Das AK, et al. Journal of Pharmacological Sciences. 2008;107(2):159-66. doi:10.1254/jphs.08028fp.

47. Histamine and Cholesterol Lowering Abilities of Lactic Acid Bacteria Isolated From Artisanal Pico Cheese. Domingos-Lopes MFP, Stanton C, Ross RP, Silva CCG. Journal of Applied Microbiology. 2020;129(6):1428-1440. doi:10.1111/jam.14733.

48. Multifunctional Lactiplantibacillus Plantarum SQ1 From Baijiu Daqu: Application of Histamine Degradation and Probiotic Potential in Yogurt Production. Tong W, Xu H, He P, et al. Food Research International (Ottawa, Ont.). 2025;203:115911. doi:10.1016/j.foodres.2025.115911.

49. Degradation of Histamine by Lactobacillus Plantarum Isolated From Miso Products. Kung HF, Lee YC, Huang YL, et al. Journal of Food Protection. 2017;80(10):1682-1688. doi:10.4315/0362-028X.JFP-17-135.

50. Microbial Patterns in Patients With Histamine Intolerance. Schink M, Konturek PC, Tietz E, et al. Journal of Physiology and Pharmacology : An Official Journal of the Polish Physiological Society. 2018;69(4). doi:10.26402/jpp.2018.4.09.

51. Metagenomic Evaluation, Antimicrobial Activities, and Immune Stimulation of Probiotics From Dietary Supplements and Dairy Products. Chornchoem P, Tandhavanant S, Saiprom N, et al. Scientific Reports. 2025;15(1):11537. doi:10.1038/s41598-025-95664-w.